Will FAA's new drone testing make flying safer?
The FAA is testing new drone detection technology along the New Jersey Shore following reports of mysterious drones spotted over parts of the East Coast last year.
Mike Fraietta, founder of Gargoyle Systems, joins 'Elizabeth Vargas Reports' to discuss whether this test can increase the safety for planes and helicopters.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
See it: Brood 14 cicadas return to Suffolk County after 17 years
LONG ISLAND, N.Y. (PIX11) — They are back! After 17 years, the Brood 14 cicadas have emerged in Suffolk County, with hundreds of thousands making quite the racket. Photojournalist Keith Lopez has the story from Port Jefferson Station. If you see a Brood 14 cicada in your neighborhood, take a picture and submit it online. Watch the video player for the full interview. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
AVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards
VALENCIA, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced that RECELLⓇ, including RECELLⓇ GO, has been recognized as the 'Best New Technology Solution – Surgical' in the 2025 MedTech Breakthrough Awards. RECELL, FDA-approved for thermal burn wounds and full-thickness skin defects, has treated over 30,000 patients worldwide. RECELL requires significantly less donor skin than traditional grafting, reducing donor-site pain and accelerating recovery. Additional clinical outcomes include fewer procedures, improved functional and aesthetic results, and shorter hospital stays. RECELL GO retains these clinical benefits while enhancing procedural consistency and surgical team coordination, with the physician remaining central throughout the procedure. This design supports adoption in high-volume burn and trauma centers, and enables scalable, cost-efficient deployment across acute wound care settings. 'We appreciate this recognition, which highlights RECELL's advantages in burn and trauma care,' said Jim Corbett, Chief Executive Officer of AVITA Medical. 'By requiring significantly less donor skin than traditional grafting, RECELL reduces donor-site pain, accelerates healing and improves patient outcomes. We remain committed to expanding access and advancing care for patients.' The MedTech Breakthrough Awards honor companies and products shaping healthcare's future. The 2025 program drew over 4,500 nominations globally. In addition to this recognition, Dr. Katie Bush, Senior Vice President of Scientific & Medical Affairs of AVITA Medical, was awarded the 2025 Emerald Pinnacle Healthcare Award in the Medical Device category. The Pinnacle Award celebrates companies and individuals who have demonstrated exceptional innovation, leadership, and impact in healthcare. About AVITA Medical, Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL System®, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient's own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point of care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix. In international markets, the RECELL System is approved to promote skin healing in a wide range of applications, including burns, full-thickness skin defects, and vitiligo. The RECELL System, excluding RECELL GO™, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan. To learn more, visit Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'future,' 'goal,' 'guidance,' 'intend,' 'look forward,' 'may,' 'outlook,' 'project,' 'target,' 'will,' 'would,' and similar words or expressions, and the use of future dates. Forward-looking statements include, but are not limited to, statements relating to the timing and realization of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company's control. These statements are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the 'Risk Factors' section of the Company's latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties. Authorized for release by the Chief Financial Officer of AVITA Medical, Inc. CONTACT: Investor & Media Contact: Jessica Ekeberg investor@ media@
Yahoo
2 hours ago
- Yahoo
Asana, Inc. (ASAN) Beats Q1 Earnings and Revenue Estimates
Asana, Inc. (ASAN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 150%. A quarter ago, it was expected that this company would post a loss of $0.01 per share when it actually produced break-even earnings, delivering a surprise of 100%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Asana , which belongs to the Zacks Internet - Software industry, posted revenues of $187.27 million for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 1.31%. This compares to year-ago revenues of $172.45 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Asana shares have lost about 9.3% since the beginning of the year versus the S&P 500's gain of 0.9%. While Asana has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Asana: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.03 on $191.32 million in revenues for the coming quarter and $0.19 on $772.77 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 22% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Rubrik, Inc. (RBRK), is yet to report results for the quarter ended April 2025. The results are expected to be released on June 5. This company is expected to post quarterly loss of $0.33 per share in its upcoming report, which represents a year-over-year change of +79.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Rubrik, Inc.'s revenues are expected to be $260.22 million, up 38.9% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Asana, Inc. (ASAN) : Free Stock Analysis Report Rubrik, Inc. (RBRK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
